Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Rats given an intraplantar carrageenan injection to produce paw inflammation
- Dose used in the study
- micronised PEA (PEA-m, 10 mg/kg) or ultramicronised PEA (PEA-um, 10 mg/kg) or nonmicronised PEA (PeaPure, 10 mg/kg), given by mouth or into the abdomen
- Duration
- Not stated in the abstract
- What was measured
- Inflammatory cell infiltration, myeloperoxidase activity, paw swelling and thermal hyperalgesia, comparing oral and intraperitoneal dosing across the three PEA formulations.
What the authors reported
Oral micronised and ultramicronised PEA (10 mg/kg) reduced inflammatory cell infiltration, myeloperoxidase activity, paw swelling and thermal hyperalgesia, but oral nonmicronised PEA (PeaPure, 10 mg/kg) did not. When given into the abdomen instead, all three formulations were effective.
Limits of this study
A rat model of carrageenan-induced paw inflammation; it cannot show effect in people. PubMed lists an erratum for this paper (J Neuroinflammation. 2016;13(1):129). Funding and conflicts not stated in the abstract.
Source
PubMed 25164769 · doi:10.1186/s12974-014-0136-0
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.